Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$13.5M, compared with $27.8M a year earlier. Trailing-twelve-month net change in cash was -$19.32M.
Context
- Net change in cash amounted to 181.0% of revenue in FY2025, down 2.1 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$13.5M or moves back toward the trailing-twelve-month quarterly average of -$4.83M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 21.97M USD
- Year-over-year change
- +271.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.97M | +271.4% |
| FY2024 | 2024-12-31 | (12.82M) | -141.2% |
| FY2023 | 2023-12-31 | (5.31M) | -334.5% |
| FY2022 | 2022-12-31 | (1.22M) | +99.3% |
| FY2021 | 2021-12-31 | (182.44M) | — |
Net Change in Cash vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -224.2% is the 10th highest of 11, against a peer median of +195.3%.
- Net change in cash amounts to 115.6% of revenue for PRLD, versus a peer median of 126.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $100M USD | -769.9% | +42.0% | 169491.5% | |
| LTM Mar 2026 | $27.89M USD | +253.0% | — | 98.8% | |
| LTM Mar 2026 | $27.12M USD | +568.0% | +19.1% | 12051.1% | |
| LTM Mar 2026 | $25.29M USD | +542.2% | -17.4% | 36.5% | |
| LTM Mar 2026 | $19.32M USD | -224.2% | — | 115.6% | |
| LTM Mar 2026 | $17.36M USD | -13.1% | -72.2% | 155.0% | |
| FY2025 | €14.17M EUR | -79.7% | +326.2% | 316.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $11.75M USD | +1066.8% | +102.1% | — |
| LTM Mar 2026 | $11.46M USD | +137.7% | — | — | |
| LTM Mar 2026 | $10.02M USD | +301.3% | +8.1% | 30.6% | |
| LTM Mar 2026 | $6.99M USD | -54.0% | -65.1% | 50.5% | |
| Peer median (excluding PRLD) | — | +195.3% | +13.6% | 126.9% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.